Compare DexCom, Inc. (DXCM) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs PepsiCo, Inc. — how do they compare? DexCom, Inc. trades at $90.79 (market cap $34.26B), while PepsiCo, Inc. trades at $139.16 (market cap $189.31B). The key difference: PepsiCo, Inc. is far larger — about 5.5× DexCom, Inc.'s market cap, and PepsiCo, Inc. pays a 4.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PEP | |
|---|---|---|
Market Cap | $34.26B | $189.31B |
Sector | Health | Consumer Staples |
52-Week High | $90.80 | $170.44 |
52-Week Low | $54.84 | $134.95 |
Enterprise Value | $33.72B | $231.81B |
Dividend Yield | — | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
PepsiCo (PEP) trades at $138.41, up 0.52% on the day, with the stock showing mixed technical signals amid a bearish moving average trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.20 beating expectations of $2.19, and robust profitability metrics including 53.96% gross margin and 51.59% ROE. Recent news highlights price adjustments in snack categories and sponsorship changes, while analysts maintain a cautious but generally positive outlook.
PepsiCo presents a stable investment case with strong cash flow generation and dividend consistency, though near-term headwinds include pricing sensitivity in snack categories and competitive pressures. The consensus price target of $158.79 suggests 15% upside potential, supported by ongoing business transformation efforts. Key risks include consumer pushback on pricing and execution challenges in North American markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
